Applied Therapeutics (APLT) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$16.6 million.
- Applied Therapeutics' Income from Continuing Operations rose 4147.11% to -$16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.3 million, marking a year-over-year decrease of 777.86%. This contributed to the annual value of -$100.8 million for FY2024, which is 5953.17% down from last year.
- Applied Therapeutics' Income from Continuing Operations amounted to -$16.6 million in Q3 2025, which was up 4147.11% from -$22.7 million recorded in Q2 2025.
- Applied Therapeutics' 5-year Income from Continuing Operations high stood at -$10.6 million for Q1 2023, and its period low was -$32.1 million during Q4 2024.
- For the 3-year period, Applied Therapeutics' Income from Continuing Operations averaged around -$20.7 million, with its median value being -$20.5 million (2024).
- As far as peak fluctuations go, Applied Therapeutics' Income from Continuing Operations plummeted by 9278.93% in 2024, and later soared by 4147.11% in 2025.
- Quarter analysis of 3 years shows Applied Therapeutics' Income from Continuing Operations stood at -$20.7 million in 2023, then plummeted by 55.21% to -$32.1 million in 2024, then soared by 48.18% to -$16.6 million in 2025.
- Its last three reported values are -$16.6 million in Q3 2025, -$22.7 million for Q2 2025, and -$24.9 million during Q1 2025.